Personalized Medicine
Play video

Personalized Medicine

PREDYSTIC® Infliximab RA Kit

Future therapies rely on the development of Personalized Medicine, when the therapy is tailored to the patient’s anatomy, metabolism, biochemistry ultimately their genetic background.

The core of Personalized Medicine is the observation of understanding the unique nature of the actual patient based on genetic, epigenetic, and clinical information. Thus, we can predict, diagnose or cure them tailored to their individual needs.

The keys to personalized medications are reliable and cost-effective diagnostic procedures shedding light on the individual drug-patient interactions, facilitating the selection of the effective therapy, reducing side-effects thus supporting the realization of a cost-effective therapy.

Egis Pharmaceuticals PLC has started its journey in the Personalized Medicine space by developing a novel innovative diagnostic method, the PREDYSTIC® Infliximab RA Kit complying with the effective European In vitro Diagnostic Directive (IVDD) and in line with the future In vitro Diagnostic Regulation (IVDR) requirements.

In rheumatoid arthritis (RA) disease heterogeneity and interpatient variability contribute to differences in drug efficacy and safety. Since the therapeutic response shows significant differences between individuals it is an unmet medical need in everyday clinical therapy to eliminate the trial-and-error method by incorporating predictive biomarkers into therapeutic decision making.

The development of a complementary diagnostic (CLDx) PREDYSTIC® Infliximab RA Kit has covered the complete cycle from biomarker discovery through in-process manufacturing and successful clinical performance testing to EU IVDD registration. According to the definition complementary diagnostics identify a biomarker-defined subset of patients that respond particularly well to a drug and aid risk/benefit assessments for individual patients, but that are not pre-requisites for receiving the drug.

The PREDYSTIC® Infliximab RA Kit identifies those bio-naïve patients with RA, who are likely responders or non-responders to infliximab treatment based on biomarker analysis from peripheral blood sample collected before the treatment initiation.

Egis Pharmaceuticals PLC as the official manufacturer of the PREDYSTIC® Infliximab RA Kit received the CE In vitro Diagnostic (IVD) Medical Device Certificate in December 2020.

The PREDYSTIC® Infliximab RA Kit is manufactured at the Körmend site of Egis Pharmaceuticals PLC.

The PREDYSTIC® Infliximab RA Kit will be available from Q4 2021 as a Product and as a Service via our official partners. Please send your questions and inquiries to the predystic@egis.hu e-mail address.

For more information on the PREDYSTIC® Infliximab RA Kit please scroll down and visit the 1.1. Clinical need / 1.2. Development / 1.3. Clinical Performance Evaluation sections.

For the latest information, visit the Linkedin page of the PREDYSTIC® Infliximab RA Kit.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox